Clinical Trial Update: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chidamide with etoposide and cisplatin/carboplatin as first-line therapy for extrapulmonary neuroendocrine carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumors

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Chidamide (chidamide)
• Etoposide (Etoposide)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Status: UNKNOWN